Valo Therapeutics Secures EUR 2.23 million from the European Innovation Council to Progress Innovative PeptiCHIP Technology

Helsinki, Finland, 14th February 2023: Valo Therapeutics Oy (Valo Tx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, announces that it has secured funding of approximately EUR 2.23 million (around USD 2.42 million) from the European Innovation Council (EIC) for a project to progress the company’s innovative PeptiCHIP technology. PeptiCHIP rapidly identifies a tumor’s antigen presentation profile to drive development of novel personalized immunotherapies.

Read full release.